Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 31, 2023
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
[ Mon, Jul 31st 2023
] - WOPRAI
Paul Choi Maintained (URGN) at Hold with Increased Target to $18 on, Jul 31st, 2023
Paul Choi of Goldman Sachs, Maintained "UroGen Pharma Ltd." (URGN) at Hold with Increased Target from $11 to $18 on, Jul 31st, 2023.
Paul has made no other calls on URGN in the last 4 months.
There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $23 on, Wednesday, June 21st, 2023
- Leland Gershell of "Oppenheimer" Reiterated at Buy and Held Target at $22 on, Monday, May 15th, 2023
